The primary purpose of this study is to determine if PD-0299685 is effective and safe in the treatment of vasomotor symptoms (hot flashes / flushes) associated with menopause.

Inclusion Criteria:

• Postmenopausal as defined by 6 months of spontaneous amenorrhea with serum FSH levels >40mlU/ml and estradiol < than = 25 pg/mL or 6 weeks post-surgical bilateral oophorectomy with or without hysterectomy and FSH levels > 40 mlU/ml and estradiol < than = 25 pg/mL
• Women reporting at least 50 moderate to severe vasomotor symptoms per week, recorded for seven consecutive days
• Aged 40 to 70 years

Exclusion Criteria:

• No estrogen monotherapy or estrogen/progesterone containing drug products within applicable wash out period prior to screening
• Use of SERMs, clonidine within 4 weeks of screening
• Use of CNS active medication within 1 week of screening
• Use of medications (SSRI; SNRI), herbal or dietary supplements, including black cohosh, soy, phytoestrogens or over the counter agent known to possibly be effective for the treatment of vasomotor symptoms, within 4 weeks of screening
• Participation in clinical trial within 30 days
• Significant medical or psychiatric illness within past 12 months